Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Medincell S.A.
Industry Sector: HealthTechnology
CEO: Christophe Douat, MBA
Number Of Employees: 134
Enterprise Value: $336,790,370
PE Ratio: -12.38
Exchange/Ticker 1: Euronext Paris:MEDCL
Exchange/Ticker 2: N/A
Latest Market Cap: $486,736,472
BioCentury | Apr 23, 2024
Deals
Deals report: Two Japanese pharmas set up local biotech incubator
Plus: Takeda licenses immuno-oncology program from Kumquat, and deals for Ipsen-Skyhawk, Boehringer-Ochre and more
BioCentury | Nov 10, 2023
Management Tracks
New CFO, CMO at TreeFrog
Plus: Metagenomi names Borges CSO and Wapnick CFO, and updates from Teva, Century, Assembly and more
BioCentury | Sep 8, 2023
Management Tracks
Greig named non-executive chair at Nucleome
Plus: updates from SparX, Breathe, Find and MedinCell
BioCentury | May 2, 2023
Finance
May 1 Quick Takes: Acelyrin could be NASDAQ’s biggest biotech IPO in two years
Plus: Translational inhibition company Initial launches with $75M from ATP and updates from Biogen, Ascendis, Minerva, Teva-MedinCell, BMS, Avadel
BioCentury | Aug 29, 2022
Regulation
Aug. 29 Quick Takes: Novartis’ Scemblix wins EU approval in leukemia setting
Plus Farxiga demonstrates survival benefit and a Teva-MedinCell antipsychotic enters Phase III
BioCentury | May 11, 2022
Management Tracks
Shea replacing Kim as CEO of Inovio
Plus new chief commercial officer at DNA Script, and updates from Boston Pharma, Quantum SI, Beta, Longeveron and more
BioCentury | Apr 20, 2022
Deals
April 19 Quick Takes: Flagship-founded Tessera raises $300M from broad syndicate
Plus: Schizophrenia setback for Teva, MedinCell and updates from BioXcel, Moderna, J&J, Unlearn, Amgen and more
Items per page:
1 - 8 of 8